Westwood Bioscience

Westwood Bioscience is a private biotechnology company developing nanomedicine and encapsulated drug delivery technologies for oncology. Its core platform, Silicasome, is a mesoporous silica nanoparticle with a lipid bilayer coating designed to improve delivery of chemotherapeutic agents to tumors while reducing systemic toxicity. Publicly available descriptions indicate the company is focused on cancer applications, with particular mention of pancreatic and colon cancer. External company databases and incubator materials describe the business as active, Los Angeles-based, and founded in 2017. The company appears to be platform-oriented rather than commercial-stage, with programs still in preclinical or IND-enabling development.